Fluorine-18 Deoxyglucose (F18-FDG)

This tender concerns the procurement of Fluorine-18 Deoxyglucose (F18-FDG), a radiopharmaceutical used in medical imaging, specifically Positron Emission Tomography (PET) scans. The contracting authority is seeking to establish a framework agreement for the supply of this essential diagnostic agent. The framework agreement will have a minimum quantity of 8 doses and a maximum of 1,800 doses. Subsequent contracts awarded under this framework will have a minimum quantity of 4 doses and a maximum of 250 doses per contract. The estimated value for the largest subsequent contract is set at 625,000.00 Romanian Leu (RON), with the overall estimated value of the procurement, excluding Value Added Tax (VAT), standing at 4,500,000.00 RON. This procurement is crucial for ensuring the continued availability of diagnostic imaging services, likely within a specific healthcare region or institution in Romania. Bidders are expected to demonstrate their capacity to supply high-quality F18-FDG consistently and reliably, meeting all relevant regulatory and quality standards for radiopharmaceuticals. Further details regarding technical specifications, delivery schedules, and evaluation criteria will be provided in the full tender documentation.

This is a supplies contract in the health and medical services and general supplies sectors, with a focus on Pharmaceuticals. Located in Romania, Europe, this opportunity is open to firms and consortiums, with an estimated budget of RON 4.5 million.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.